Lior Zangi | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Prof. Lior Zangi, Icahn School of Medicine at Mount Sinai, United States

Prof. Lior Zangi is an Associate Professor of Cardiology and Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai, NY. He earned his Ph.D. in Immunology from the Weizmann Institute and completed postdoctoral training at Harvard Medical School. Renowned for his pioneering work in mRNA-based cardiovascular therapies, Prof. Zangi has received prestigious awards including the AHA Postdoctoral Fellowship and an endowed professorship in Cardiovascular Research. He is a founding board member of the Society for RNA Therapeutics and actively contributes to global scientific councils, manuscript reviews, and grant panels.

Publication Profile

Google Scholar

Education

Prof. Lior Zangi 🎓 began his academic journey with a B.Sc. in Biology from the Hebrew University, Givat-Ram, Jerusalem in 2000. He then earned his M.Sc. in Experimental and Developmental Medicine in 2003 from the Hebrew University Hadassah-Medical School under the guidance of Prof. Raphael Gorodetsky. In 2009, he completed his Ph.D. in Immunology at the Weizmann Institute of Science, mentored by Prof. Yair Reisner. 🌿 He continued his training as a postdoctoral fellow at Sheba Medical Center (2009–2010) under Prof. Benjamin Dekel and later at Harvard Medical School (2010–2014) with Professors Derrick Rossi and Kenneth Chien.

Awards

Prof. Lior Zangi 🌟 has earned numerous prestigious honors throughout his career. He received the ASH Travel Award in both 2008 and 2009 🧳, and in 2009, was granted a Postdoctoral Fellowship Award by the Israeli Budgeting Committee and Planning. In 2012, he was honored with both the ISSCR Travel Award and R&D Systems Travel Grant ✈️. His groundbreaking postdoctoral work earned him the AHA Fellowship Award in 2014 🫀. In 2017, he received the Mount Sinai Faculty Idea Prize 🧠, and in 2019, his research on mRNA therapy was recognized as highly influential 📜. In 2023, he was awarded the Endowed Chan Soon-Shiong Professorship in Cardiovascular Research 🏅.

Research Focus

Prof. Lior Zangi is a pioneering researcher in cardiovascular regenerative medicine, with a special focus on modified mRNA therapies, 🧬 stem cell biology, and 🫀 cardiac regeneration. His work centers on developing innovative strategies for repairing damaged heart tissue using modRNA, induced pluripotent stem cells (iPSCs), and heart-on-chip technologies. Zangi’s groundbreaking research has contributed to advancements in treating conditions like myocardial infarction and Barth syndrome, and has broad implications for tissue engineering, 💉 protein replacement therapy, and immune modulation. His contributions are reshaping modern precision medicine and offering new hope for heart failure patients worldwide.

Publication Top Notes

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells

Isolation and characterization of nontubular sca-1+ lin− multipotent stem/progenitor cells from adult mouse kidney

Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration

mRNA-based protein replacement therapy for the heart

Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. 🌍💊🔬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. 🧠📚🎓

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at Mälardalen University in 1981. 🧑‍🔬💉📚

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. 🌍🔬🧠

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. 🧠💊

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. 🧠📚💊

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at Umeå University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. 🎓🧠💡

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. 🧠💊🎓

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. 🧠🔬💊 His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Dr. ANANDARUP GOSWAMI| Drug Discovery and Developmenty|Best Researcher Award

Published on by Top Pharmaceutical

Dr. ANANDARUP GOSWAMI| Drug Discovery and Development|Best Researcher Award

Dr. ANANDARUP GOSWAMI at Vignan’s Foundation for Science, Technology and Research,India

PROFILE  

Google scholar

Early Academic Pursuits 🎓

Dr. Anandarup Goswami’s passion for chemistry was ignited during his early years of education. He completed his undergraduate studies with a B.Sc. (Hons.) in Chemistry from the prestigious Presidency University in Kolkata, one of India’s top institutions for the sciences. He further honed his expertise by pursuing an M.Sc. in Chemistry at the renowned Indian Institute of Technology (IIT) Kanpur, known for producing some of the finest scientific minds in the country. Dr. Goswami’s dedication to his academic pursuits earned him a place in Cornell University, USA, where he completed his Ph.D. His doctoral work marked the beginning of his contribution to cutting-edge research, where he specialized in advanced areas of chemistry. His journey did not stop there; he went on to complete his postdoctoral research at Rutgers University, USA, and Palacky University, Czech Republic, enhancing his research portfolio and gaining exposure to diverse scientific methodologies and innovative research techniques.

Professional Endeavors 🧪

Dr. Anandarup Goswami joined Vignan’s Foundation for Science, Technology and Research (VFSTR) as an Associate Professor in November 2026. His professional career spans a broad spectrum of roles, from teaching and mentoring students to leading groundbreaking research. He has served as a Ph.D. supervisor and has guided numerous students in drug degradation studies and nanocatalysis development for environmental applications. His work at VFSTR has helped shape the future of young scientists while driving forward critical research in sustainable chemistry.

Dr. Goswami also holds numerous editorial appointments, including being a member of the Editorial Board of Current Indian Science (Bentham) and a Review Editor for Green and Sustainable Chemistry (Frontiers). His contributions to these roles highlight his prominence in the scientific community, where he is trusted to review and oversee publications in these significant areas of research.

Contributions and Research Focus 🔬

Dr. Goswami’s research contributions are primarily centered around two critical areas: pharmaceutically relevant compounds and sustainable nanocatalysts. His extensive work in the isolation and in-depth characterization of degradation products of pharmaceutical compounds has significant implications for drug safety, efficacy, and regulatory science. In tandem, his pioneering work on the development of nanocatalysts for environmental applications addresses pressing issues related to sustainability and environmental protection.

Dr. Goswami’s work emphasizes catalysis, energy conversion, and material science, offering solutions to some of today’s most critical challenges. His contributions span more than 50 peer-reviewed publications, including in highly reputed journals such as Journal of the American Chemical Society (JACS), Angewandte Chemie, and Nature Chemistry. Moreover, his book, Solvent-Free Methods in Nanocatalysis: From Catalyst Design to Applications, co-edited with prominent scientists, reflects his authority in the field of nanocatalysis.

Accolades and Recognition 🏆

Dr. Goswami’s research accomplishments have been widely recognized in the scientific community. With an h-index of 27 on Google Scholar and 26 on Scopus, along with more than 8,800 citations, his work has made a lasting impact on his field. He has received recognition for his contributions to nanocatalysis and drug degradation, and his research has gained international acclaim.

One of his notable patents, US010722743B2, titled Multicatalyst Polyelectrolyte Membranes and Methods of Utilizing the Same, was developed during his time at Rutgers University, USA. This patent reflects his innovative approach to solving complex problems in material science and catalysis.

Dr. Goswami’s contributions have also led him to collaborate with renowned scientists globally, including Prof. Tewodros Asefa from Rutgers University, USA, and Prof. Radek Zboril from RCPTM, Czech Republic. These collaborations have expanded his research’s scope and influence, enabling him to contribute to international advancements in chemistry.

🎓Publication 

Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis

  • Authors   : Manoj B Gawande, Anandarup Goswami, François-Xavier Felpin, Tewodros Asefa, Xiaoxi Huang, Rafael Silva, Xiaoxin Zou, Radek Zboril, Rajender S Varma
  • Journal    :Chemical reviews
  • Year         :2016

obalt‐Embedded Nitrogen‐Rich Carbon Nanotubes Efficiently Catalyze Hydrogen Evolution Reaction at All pH Values

  • Authors   : Xiaoxin Zou, Xiaoxi Huang, Anandarup Goswami, Rafael Silva, Bhaskar R Sathe, Eliška Mikmeková, Tewodros Asefa
  • Journal    :Angewandte Chemie International Edition
  • Year         :2014

Core–shell nanoparticles: synthesis and applications in catalysis and electrocatalysis

  • Authors   : Manoj B Gawande, Anandarup Goswami, Tewodros Asefa, Huizhang Guo, Ankush V Biradar, Dong-Liang Peng, Radek Zboril, Rajender S Varma
  • Journal    :Chemical Society Reviews
  • Year         :2015

Covalent functionalization of monolayered transition metal dichalcogenides by phase engineering

  • Authors   : Damien Voiry, Anandarup Goswami, Rajesh Kappera, Cecilia de Carvalho Castro e Silva, Daniel Kaplan, Takeshi Fujita, Mingwei Chen, Tewodros Asefa, Manish Chhowalla
  • Journal    :Nature chemistry
  • Year         :2015

Covalent functionalization of monolayered transition metal dichalcogenides by phase engineering

  • Authors   :Damien Voiry, Anandarup Goswami, Rajesh Kappera, Cecilia de Carvalho Castro e Silva, Daniel Kaplan, Takeshi Fujita, Mingwei Chen, Tewodros Asefa, Manish Chhowalla
  • Journal    :Nature Publishing Group
  • Year         :2015

Prof. Maysoon Al-Haideri| Drug Discovery |Best Researcher Award

Published on by Top Pharmaceutical

Prof. Maysoon Al-Haideri|Drug Discovery|Best Researcher Award

Prof. Maysoon Al-Haideri at University oh Kurdistan Hewlêr,Iraq

PROFILE  

scopus 

 

Early Academic Pursuits 🎓

Dr. Al-Haideri began her educational journey at Baghdad University, where she completed her B.Sc. in Pharmacy in 1973. She demonstrated early promise and a strong interest in clinical analysis, leading her to pursue an Advanced Diploma in Clinical Analysis from Baghdad University between 1977 and 1979. Her academic curiosity and pursuit of excellence took her to the United States, where she attended Columbia University in the City of New York, earning a Master of Arts (M.A.) in 1983, followed by an M.Phil. in Pathology in 1985. Her dedication and passion culminated in a Ph.D. in Pathology from Columbia University in 1987, marking the beginning of an illustrious career in clinical research and academia.

Professional Endeavors 🩺

Dr. Al-Haideri’s professional career began in Iraq, where she gained practical experience and took on leadership roles in several medical institutions. She completed a traineeship in Clinical Hematology, Clinical Biochemistry, Medical Microbiology, Parasitology, and Infectious Diseases at the Ministry of Health in Baghdad from 1974 to 1975. Following this, she served as the Director of the Clinical Laboratory at Abo-Alkhaseab Hospital in Basrah (1975-1976) and Chief of the Clinical Biochemistry and Hematology Divisions at Al-Khadmia Teaching Hospital in Baghdad (1976-1981). During this time, she was also responsible for student supervision and training, highlighting her commitment to fostering the next generation of healthcare professionals.

From 1981 to 1982, Dr. Al-Haideri took on a national role as the Director of Quality Control and Standardization for all public clinical laboratories in Iraq, ensuring the consistent application of best practices in clinical analysis. Her leadership and expertise were further recognized when she undertook a traineeship in infertility at the Ministry of Health in Baghdad in 1982, signaling her growing influence in medical diagnostics and reproductive health.

In the United States, Dr. Al-Haideri continued her impressive trajectory, completing a postdoctoral fellowship at North Shore University Hospital, Manhasset, New York (1987-1988), followed by research positions at Long Island Jewish Medical Center (1988-1990) and Albert Einstein College of Medicine, Bronx, New York (1989-1991). During this time, she held the title of Instructor of Immunology, Rheumatology, and Allergy. Dr. Al-Haideri’s academic and research career reached new heights when she joined Columbia University’s College of Physicians and Surgeons, where she worked as an NIH Postdoctoral Research Trainee (1991-1994), eventually becoming an Associate Research Scientist and Assistant Professor (1994-2004).

Contributions and Research Focus 🔬

Dr. Al-Haideri’s research has primarily focused on clinical pathology, immunology, rheumatology, and allergy. Her work has been instrumental in enhancing the understanding of immunological responses in various pathological conditions. She has been actively involved in numerous research projects, often collaborating with leading medical institutions in both the U.S. and Iraq.

Her role as Director of Quality Control and Standardization in Iraq’s Ministry of Health laid the groundwork for the development of national policies aimed at ensuring the accuracy and reliability of clinical laboratory diagnostics across the country. In the U.S., her work at prestigious institutions like Columbia University and Albert Einstein College of Medicine helped advance the field of immunology, particularly in relation to autoimmune diseases.

Accolades and Recognition 🏆

Dr. Al-Haideri’s work has been widely recognized through various awards and honors. She received NIH Grant Awards from 1991 to 1994, which supported her groundbreaking research in immunology and pathology. Her academic excellence was also acknowledged at Columbia University, where she was awarded Graduate Research Assistantships.

Her commitment to medical education and healthcare development in Iraq earned her numerous accolades, including being named Employee of the Year at Hawler Medical University in Erbil, Kurdistan in 2012. Additionally, she received letters of appreciation from the Minister of Higher Education and Scientific Research in the Kurdistan region, as well as from the President of Hawler Medical University and several deans of colleges at the university for her contributions to education and healthcare.

Impact and Influence 🌍

Dr. Al-Haideri has had a profound impact on medical education and healthcare both in Iraq and abroad. As a leader in various institutions, she has played a critical role in shaping the medical education system in the Kurdistan Region of Iraq. Her tenure as Dean of the College of Health Sciences at Hawler Medical University (2014-2018) and Director of Quality Assurance (2010-2015) helped set new standards for academic excellence and institutional leadership in the region.

Her influence extends beyond academia. Dr. Al-Haideri has been an active member of numerous professional societies, including the American Society for Biochemistry and Molecular Biology and the American Heart Association, further cementing her status as a respected expert in her field. Her involvement in international organizations, such as the International Institute of Education in New York, reflects her commitment to global collaboration and knowledge exchange.

Legacy and Future Contributions 🔮

Dr. Maysoon Tahir Al-Haideri’s legacy is one of dedication to advancing medical knowledge, improving healthcare systems, and fostering academic excellence. Her work has had a lasting impact on the clinical and academic landscapes in Iraq, particularly in the Kurdistan region, where she has influenced generations of healthcare professionals through her leadership roles at Hawler Medical University and Cihan University-Erbil.

As she continues her work as the Director of the Pharmacy Program at the University of Kurdistan Hewler, Dr. Al-Haideri remains committed to mentoring students and contributing to the development of the healthcare sector in the region. Her achievements serve as an inspiration to future generations of scientists, educators, and healthcare professionals, ensuring her legacy will endure for years to come.

🎓Publication 

Silymarin suppresses proliferation and PD-L1 expression in colorectal cancer cells and increases inflammatory CD8+ cells in tumor-bearing mice

  • Authors   :Al-Haideri, M.
  • Journal    :Clinics and Research in Hepatology and Gastroenterology
  • Year         :2024

Functional and financial analysis of an inclined step solar desalination using phase change nanomaterials

  • Authors   : Mahal, A., Al-Haideri, M., Alkhouri, A., Obaidullah, A.J., Duan, M.
  • Journal    :Water Science and Technology
  • Year         :2024

Tuning the optoelectronic properties of selenophene-diketopyrrolopyrrole-based non-fullerene acceptor to obtain efficient organic solar cells through end-capped modification

  • Authors   :Ijaz, R., Waqas, M., Mahal, A., … Alatawi, N.S., Aloui, Z.
  • Journal    :Journal of Molecular Graphics and Modelling,
  • Year         :2024

Rational designing of phenothiazine dioxide based hole transporting materials for efficient perovskite solar cells

  • Authors   : Hanan, M., Umair, Mahal, A., … Farooq, Z., Mahr, M.S.
  • Journal    : Solar Energy,
  • Year         :2024

Linking the increasing epidemiology of scrub typhus transmission in India and South Asia: are the varying environment and the reservoir animals the factors behind?

  • Authors   : Mohapatra, R.K., Al-Haideri, M., Mishra, S., … Mohanty, A., Sah, R.
  • Journal    :Frontiers in Tropical Diseases,
  • Year         :2024

Dr. Rajendra Rohokale|Drug Discovery and Development| Best Researcher Award

Published on by Top Pharmaceutical

Dr. Rajendra Rohokale| Drug Discovery and Development ,Best Researcher Award

Dr. Rajendra Rohokale at university of florida,United States

PROFILE  

Orcid

🎓Early Academic Pursuits :

Dr. Rajendra Shankarrao Rohokale embarked on his academic journey with a strong foundation in the sciences, earning his Bachelor of Science in Chemistry from New Arts, Science, and Commerce College, Ahmednagar, affiliated with Savitribai Phule Pune University, Pune, India. His academic pursuit continued with a Master of Science in Organic Chemistry from the same university, where he honed his skills in synthetic organic chemistry, laying the groundwork for his future research endeavors.

During his postgraduate studies, Dr. Rohokale demonstrated a profound interest in organic chemistry, particularly in the areas of synthetic carbohydrate chemistry and glycoscience. His early academic years were marked by a commitment to exploring the complexities of organic compounds, setting the stage for his later achievements in the field.

💼Professional Endeavors :

Dr. Rohokale’s professional journey is characterized by significant contributions to the field of synthetic organic chemistry, with a focus on carbohydrate chemistry, glycoscience, and photoredox catalysis. After completing his Ph.D. in Organic Chemistry from the Department of Chemistry, Savitribai Phule Pune University, he joined the University of Florida as a Research Assistant Professor. Under the mentorship of Prof. Zhongwu Guo, a prominent figure in carbohydrate chemistry, Dr. Rohokale’s work primarily involved the synthesis of complex carbohydrates and their conjugates for therapeutic applications.

Before his tenure at the University of Florida, Dr. Rohokale held a prestigious SERB National Post-doctoral Fellowship at the National Chemical Laboratory, Pune, where he worked under the guidance of Dr. C. V. Ramana. His research during this period focused on the applications of iridium-catalyzed reactions and photoredox catalysis in organic chemistry, contributing to the development of new methodologies in the field.

Dr. Rohokale’s professional experience also includes an international collaboration during the Indigo Program-2012, where he worked on visible light photoredox-catalysis with Prof. Burkhard Koenig at the University of Regensburg, Germany. This collaboration further enriched his research profile, leading to innovative contributions in organic synthesis.

🔬Contributions and Research Focus :

Dr. Rohokale has made significant contributions to the fields of synthetic organic chemistry, carbohydrate chemistry, and photoredox catalysis. His research primarily focuses on developing practical and efficient methods for the chemical and chemoenzymatic synthesis of complex oligosaccharides and glycoconjugates. These include glycoproteins and glycolipids, which are applied to studying related biological and medical problems, such as the functions of glycans and their relationships with diseases.

One of Dr. Rohokale’s notable research contributions is in the area of glycolipids synthesis. His work on glycosylated liposomes for targeted drug delivery and vaccination has potential applications in diagnosing and treating human diseases, including cancer and bacterial infections. His research also extends to the synthesis of biologically relevant molecules, such as GSLs, and their use as probes to explore disease mechanisms.

🏅Accolades and Recognition :

Dr. Rohokale’s academic and research excellence has been recognized through various awards and honors. He was selected for the prestigious SERB National Post-doctoral Fellowship in 2017, acknowledging his potential to contribute to scientific research in India. His selection as a Post-doctoral Fellow at the University of Florida in 2019 further underscores his expertise in carbohydrate chemistry and organic synthesis.

Additionally, Dr. Rohokale has been an active peer reviewer for several high-impact journals, including Chemical Communication and Organic Chemistry Frontiers, published by the Royal Society of Chemistry, and The Journal of Carbohydrate Chemistry, published by the American Chemical Society. His role as a reviewer highlights his standing in the scientific community and his commitment to advancing research in his field.

🌍Impact and Influence :

Dr. Rohokale’s research has had a profound impact on the field of synthetic organic chemistry, particularly in the areas of carbohydrate chemistry and photoredox catalysis. His work on the synthesis of complex carbohydrates and glycoconjugates has implications for medical science, particularly in understanding the role of glycans in diseases and developing new diagnostic tools and therapeutic approaches.

His innovative methodologies in organic synthesis have influenced researchers globally, contributing to the development of new strategies for synthesizing biologically relevant molecules. His collaboration with international institutions, including his work in Germany and the USA, has further extended his influence, making him a respected figure in his field.

🌟Legacy and Future Contributions :

As Dr. Rohokale continues his research at the University of Florida, his legacy in synthetic organic chemistry and carbohydrate research is expected to grow. His contributions to the development of new synthetic methods and their applications in medical science position him as a leading researcher with the potential to make groundbreaking discoveries in the future

🎓Publication 

Diastereoselective 1,3-dipolar intramolecular nitrone olefin cycloaddition (INOC) reaction of a sugar-derived allyl alcohol: Synthesis of functionalized aminocyclopentitols

  • Authors   :Rajendra Rohokale
  • Journal    :
    Carbohydrate Research
  • Year         :2024

Bifunctional glycosphingolipid (GSL) probes to investigate GSL-interacting proteins in cell membranes

  • Authors :Sayan Kundu; Rajendra Rohokale; Chuwei Lin; Sixue Chen; Shayak Biswas; Zhongwu Guo
    • Journal   :
      Journal of Lipid Research
    • Year       : 2024

Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants

  •  Authors  :Rajendra Rohokale; Jiatong Guo; Zhongwu Guo
  • Journal    :
    Journal of Medicinal Chemistry

    Year         :  2024

Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines

  • Authors  :: Rajendra Rohokale; Zhongwu Guo
  • Journal   :
    ACS Infectious Diseases
  • Year        :   2023

Structural characterization and analysis of different epimers of neutral glycosphingolipid LcGg4 by ion mobility spectrometry-mass spectrometry

  • Authors  :Gao, T.; Lott, A.A.; Huang, F.; Rohokale, R.; Li, Q.; Olivos, H.J.; Chen, S.; Guo, Z.
  • Journal   :
    Analyst
  • Year        :  2022